Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Edgewise Therapeutics Inc’s stock clocked out at $22.94, down -2.67% from its previous closing price of $23.57. In other words, the price has decreased by -$2.67 from its previous closing price. On the day, 1.04 million shares were traded. EWTX stock price reached its highest trading level at $23.96 during the session, while it also had its lowest trading level at $22.78.
Ratios:
To gain a deeper understanding of EWTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 26.51 and its Current Ratio is at 26.51. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on September 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $20.
On July 30, 2025, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $46.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $42.H.C. Wainwright initiated its Buy rating on June 30, 2025, with a $42 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 26 ’25 when ROBERT MICHAEL CARRUTHERS bought 116,665 shares for $26.06 per share.
ROBERT MICHAEL CARRUTHERS bought 70,000 shares of EWTX for $1,566,586 on Nov 17 ’25. On Nov 12 ’25, another insider, Russell Alan J, who serves as the Chief Scientific Officer of the company, sold 100,000 shares for $21.12 each. As a result, the insider received 2,112,450 and left with 23,400 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EWTX now has a Market Capitalization of 2428621824 and an Enterprise Value of 1869462912.
Stock Price History:
The Beta on a monthly basis for EWTX is 0.28, which has changed by -0.07277733 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, EWTX has reached a high of $30.48, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is 4.70%, while the 200-Day Moving Average is calculated to be 38.30%.
Shares Statistics:
It appears that EWTX traded 1.36M shares on average per day over the past three months and 2023430 shares per day over the past ten days. A total of 105.76M shares are outstanding, with a floating share count of 76.46M. Insiders hold about 27.78% of the company’s shares, while institutions hold 79.09% stake in the company. Shares short for EWTX as of 1765756800 were 10522544 with a Short Ratio of 7.74, compared to 1763078400 on 10045672. Therefore, it implies a Short% of Shares Outstanding of 10522544 and a Short% of Float of 11.66.
Earnings Estimates
The dynamic stock of Edgewise Therapeutics Inc (EWTX) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.39 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.56 and -$1.66 for the fiscal current year, implying an average EPS of -$1.6. EPS for the following year is -$1.98, with 10.0 analysts recommending between -$1.5 and -$2.34.
